Abstract
Tezosentan, an endothelin receptor antagonist, is under development for the treatment of acute heart failure. Impaired renal function is a frequent comorbidity in these patients. To assess the pharmacokinetics and tolerability of tezosentan in 8 patients with severe renal impairment (creatinine clearance < 30 ml/min) compared to 8 healthy subjects. Tezosentan was infused at a rate of 100 mg/h for 1 h. Blood and urine samples were collected for pharmacokinetic determinations. Vital signs, ECG, adverse events and clinical laboratory parameters were monitored to assess tolerability. The mean (95% confidence interval) volume of distribution and clearance of tezosentan in renal patients were 15 (13, 18) l and 42 (34, 52) l/h, respectively, and did not differ significantly from the values of 18 (15, 20) l and 36 (29, 44) l/h found in healthy subjects. In patients, the renal excretion of tezosentan was impaired. Tezosentan caused a decrease in blood pressure and was well tolerated in both groups. No clinically relevant effects of severe renal impairment on the pharmacokinetics and tolerability of tezosentan were found. Therefore, no dose adjustment oftezosentan is deemed necessary in patients with any grade of renal impairment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International journal of clinical pharmacology and therapeutics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
